BioNTech SE (BNTX) stock
BNTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$83.26−1.60 (-1.89%)
Close on Nov 18, 2026Market cap $20.92BP/E –Yield –
BioNTech revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
For fiscal 2025 it was €2.87B, up 4.3% from the year before. The highest annual figure on record is €18.98B in fiscal 2021.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €2.87B | +4.3% |
| FY2024 | Dec 31, 2024 | €2.75B | -28.0% |
| FY2023 | Dec 31, 2023 | €3.82B | -77.9% |
| FY2022 | Dec 31, 2022 | €17.31B | -8.8% |
| FY2021 | Dec 31, 2021 | €18.98B | +3834.6% |
| FY2020 | Dec 31, 2020 | €482.30M | +344.1% |
| FY2019 | Dec 31, 2019 | €108.60M | -14.9% |
| FY2018 | Dec 31, 2018 | €127.58M | +107.1% |
| FY2017 | Dec 31, 2017 | €61.60M | – |
See a number that looks wrong?